The impact of hydroxychloroquine and azithromycin on the corrected qt interval in patients with the novel coronavirus disease 2019

Conclusion: Patients who received HCQ for COVID-19 were at high risk of QTc prolongation, and concurrent treatment with AZT was associated with greater changes in QTc. Comparison of baseline characteristics aCharacteristicTotal (n  = 155)Hydroxychloroquine (n = 102)Hydroxychloroquine /Azithromycin (n = 53)P valueLength of stay at ward, SD9.54 ± 4.289.64 ± 4.319.31 ± 4.250.88Length of stay Intensive care unite,SD7.92 ± 3.767.18 ± 3.188.46 ± 4.150.29Radiographic findings of pneumo nia118(76.1%)76(74.5%)42(49.2%)0.32Mechanically ventilation16(10.3%)7(6.9%)9(17.0%)0.049In hospital death19(12.3%)10(9.8%)9(17.0%)0.15ECG findings median(IQR) (ms)Baseline QRS duration91.0(80.0-103.0)92.5(80.75-105.50)90.0(80.0-102.5)0.5Posttreatment QRS peak97.0(86.0-109.0)97.5(88.0-109.25)95.0(85. 5-109)0.68ΔQRS4.0(0.0-9.0)2.0(0.0-8.25)5.0(1.0-9.5)0.14Baseline QTc duration407.0(385.0-426.0)408.0(389.25-427.50)404.0(384.0-420.0)0.1Posttreatment QTc peak437.0(414.0-460.0)428.0(412.75-449.25)456.0(422.0-467.5)<0.001 ΔQTc27.0(13.0-45.0)18.0(11.0-30.0)46.0(40.5-54.5)<0.001Baseline PR duration145.50(128.7-160.0)147.0(135.0-160.0)144.0(120.0-160.0)0.53Posttreatment PR peak159.0(140.0-170.0)159.0(141.0-168.50)156.0(139.5-171.0)0.97 ΔPR7.0(1.0-13.0)5.0(0.0-12.25)10.0(5.0-15.0)0.022QTc peak day5.0(4.0-5.0)5.0(4.0-6.0)4.0(3.0-5.0)0.022Drug withdrawl due to QRS prolongation11(7.1%)5(4.9%)6(11.3%)0.12
Source: Europace - Category: Cardiology Source Type: research